GSK Sues Barr Over Prostate Treatment Patents

Law360, New York (February 26, 2008, 12:00 AM EST) -- GlaxoSmithKline has filed a patent suit against Barr Pharmaceuticals Inc., claiming infringement of three patents covering its enlarged-prostate treatment, Avodart.

In a complaint filed Monday in the U.S. District Court for the District of Delaware, SmithKline Beecham Corp., doing business as GSK, alleged Barr’s recent abbreviated new drug application filed with the U.S. Food and Drug Administration seeks to infringe GSK’s patents before they expire.

All three patents relate to Avodart and its active ingredient, dutasteride, which is used to treat “symptomatic benign prostatic hyperplasia,” or...
To view the full article, register now.